We are pleased to announce our collaboration with Wellesta, our strategic partner, for commercialization of VECanDx ELISA test in Lebanon, Iraq & Egypt markets for early detection of bladder cancer.
This strategic advancement aims to bring this non-invasive, affordable, and highly efficient product for early detection and better management of bladder cancer treatment in Hematuria patients and high-risk individuals, for enhanced patient outcomes.
Mohamad Rammal, CEO of CureLeads, shared his enthusiasm, stating, “We are excited to bring the VECanDx ELISA bladder cancer detection kit to Lebanon, Iraq, and Egypt. This collaboration with Wellesta reflects our shared commitment to introducing affordable, non-invasive technologies that play a vital role in the early detection of bladder cancer, enabling efficient patient treatment across the region.”
Milan Paleja, Chairman & Managing Director of Wellesta, added, “With CureLeads as our strategic partner in MENA, we are confident to enhance clinical practices for bladder cancer screening for efficient treatment. Through the commercialization of this innovative and cost-effective technology, we aim to significantly improve patient outcomes in these regions.”